Skip Header

You are using a version of Internet Explorer that may not display all features of this website. Please upgrade to a modern browser.
Contribute Send feedback
Read comments (?) or add your own

P01024 (CO3_HUMAN) Reviewed, UniProtKB/Swiss-Prot

Last modified April 16, 2014. Version 182. Feed History...

Clusters with 100%, 90%, 50% identity | Documents (6) | Third-party data text xml rdf/xml gff fasta
to top of pageNames·Attributes·General annotation·Ontologies·Interactions·Sequence annotation·Sequences·References·Web links·Cross-refs·Entry info·DocumentsCustomize order

Names and origin

Protein namesRecommended name:
Complement C3
Alternative name(s):
C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1
Gene names
Name:C3
Synonyms:CPAMD1
OrganismHomo sapiens (Human) [Reference proteome]
Taxonomic identifier9606 [NCBI]
Taxonomic lineageEukaryotaMetazoaChordataCraniataVertebrataEuteleostomiMammaliaEutheriaEuarchontogliresPrimatesHaplorrhiniCatarrhiniHominidaeHomo

Protein attributes

Sequence length1663 AA.
Sequence statusComplete.
Sequence processingThe displayed sequence is further processed into a mature form.
Protein existenceEvidence at protein level

General annotation (Comments)

Function

C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates. Ref.5 Ref.11 Ref.14 Ref.15 Ref.16 Ref.22 Ref.25 Ref.29

Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes. Ref.5 Ref.11 Ref.14 Ref.15 Ref.16 Ref.22 Ref.25 Ref.29

Acylation stimulating protein: adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial TG clearance. Appears to stimulate TG synthesis via activation of the PLC, MAPK and AKT signaling pathways. Ligand for C5AR2. Promotes the phosphorylation, ARRB2-mediated internalization and recycling of C5AR2 (Ref.5, Ref.11, Ref.14, Ref.16, Ref.22, Ref.25, Ref.29). Ref.5 Ref.11 Ref.14 Ref.15 Ref.16 Ref.22 Ref.25 Ref.29

Subunit structure

C3 precursor is first processed by the removal of 4 Arg residues, forming two chains, beta and alpha, linked by a disulfide bond. C3 convertase activates C3 by cleaving the alpha chain, releasing C3a anaphylatoxin and generating C3b (beta chain + alpha' chain). C3dg interacts with CR2 (via the N-terminal Sushi domains 1 and 2). During pregnancy, C3dg exists as a complex (probably a 2:2:2 heterohexamer) with AGT and the proform of PRG2. Interacts with VSIG4. C3b interacts with herpes simplex virus 1 (HHV-1) and herpes simplex virus 2 (HHV-2) envelope glycoprotein C; this interaction inhibits the activation of the complement system. Interacts with S.aureus immunoglobulin-binding protein sbi, this prevents interaction between C3dg and CR2. Interacts with S.aureus fib. Interacts (both C3a and ASP) with C5AR2; the interaction occurs with higher affinity for ASP, enhancing the phosphorylation and activation of C5AR2, recruitment of ARRB2 to the cell surface and endocytosis of GRP77. Ref.7 Ref.10 Ref.17 Ref.18 Ref.30 Ref.31 Ref.43 Ref.44

Subcellular location

Secreted.

Tissue specificity

Plasma. The acylation stimulating protein (ASP) is expressed in adipocytes and released into the plasma during both the fasting and postprandial periods. Ref.15 Ref.22

Post-translational modification

C3b is rapidly split in two positions by factor I and a cofactor to form iC3b (inactivated C3b) and C3f which is released. Then iC3b is slowly cleaved (possibly by factor I) to form C3c (beta chain + alpha' chain fragment 1 + alpha' chain fragment 2), C3dg and C3f. Other proteases produce other fragments such as C3d or C3g. C3a is further processed by carboxypeptidases to release the C-terminal arginine residue generating the acylation stimulating protein (ASP). Levels of ASP are increased in adipocytes in the postprandial period and by insulin and dietary chylomicrons.

Phosphorylation sites are present in the extracellular medium.

Polymorphism

There are two alleles: C3S (C3 slow), the most common allele in all races and C3F (C3 fast), relatively frequent in Caucasians, less common in Black Americans, extremely rare in Orientals.

Involvement in disease

Complement component 3 deficiency (C3D) [MIM:613779]: A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis.
Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.32 Ref.35 Ref.36 Ref.37 Ref.48 Ref.49

Macular degeneration, age-related, 9 (ARMD9) [MIM:611378]: A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.
Note: Disease susceptibility is associated with variations affecting the gene represented in this entry. Ref.32 Ref.50

Hemolytic uremic syndrome atypical 5 (AHUS5) [MIM:612925]: An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease.
Note: Disease susceptibility is associated with variations affecting the gene represented in this entry. Other genes may play a role in modifying the phenotype. Ref.32 Ref.51 Ref.52

Increased levels of C3 and its cleavage product ASP, are associated with obesity, diabetes and coronary heart disease. Short-term endurance training reduces baseline ASP levels and subsequently fat storage. Ref.32

Sequence similarities

Contains 1 anaphylatoxin-like domain.

Contains 1 NTR domain.

Caution

According to Ref.44, the interaction surface between C3 and CR2 reported in Ref.36 is artifactual and can be ascribed to the presence of zinc acetate in the buffer.

Ontologies

Keywords
   Biological processComplement alternate pathway
Complement pathway
Fatty acid metabolism
Immunity
Inflammatory response
Innate immunity
Lipid metabolism
   Cellular componentSecreted
   Coding sequence diversityPolymorphism
   DiseaseAge-related macular degeneration
Disease mutation
Hemolytic uremic syndrome
   DomainSignal
   PTMCleavage on pair of basic residues
Disulfide bond
Glycoprotein
Phosphoprotein
Thioester bond
   Technical term3D-structure
Complete proteome
Direct protein sequencing
Reference proteome
Gene Ontology (GO)
   Biological_processG-protein coupled receptor signaling pathway

Traceable author statement PubMed 9164946. Source: ProtInc

complement activation

Traceable author statement. Source: Reactome

complement activation, alternative pathway

Traceable author statement. Source: Reactome

complement activation, classical pathway

Inferred from electronic annotation. Source: UniProtKB-KW

fatty acid metabolic process

Inferred from electronic annotation. Source: UniProtKB-KW

immune response

Traceable author statement PubMed 4097977. Source: ProtInc

inflammatory response

Inferred from electronic annotation. Source: UniProtKB-KW

innate immune response

Traceable author statement. Source: Reactome

positive regulation of G-protein coupled receptor protein signaling pathway

Inferred from direct assay Ref.22. Source: UniProtKB

positive regulation of activation of membrane attack complex

Inferred from electronic annotation. Source: Ensembl

positive regulation of angiogenesis

Inferred from electronic annotation. Source: Ensembl

positive regulation of glucose transport

Inferred from direct assay Ref.22Ref.14. Source: UniProtKB

positive regulation of lipid storage

Inferred from direct assay Ref.15. Source: UniProtKB

positive regulation of phagocytosis

Inferred from electronic annotation. Source: Ensembl

positive regulation of protein phosphorylation

Inferred from direct assay Ref.22. Source: UniProtKB

positive regulation of type IIa hypersensitivity

Inferred from electronic annotation. Source: Ensembl

positive regulation vascular endothelial growth factor production

Inferred from direct assay PubMed 16452172. Source: BHF-UCL

regulation of complement activation

Traceable author statement. Source: Reactome

regulation of immune response

Traceable author statement. Source: Reactome

regulation of triglyceride biosynthetic process

Inferred from direct assay Ref.16. Source: UniProtKB

signal transduction

Traceable author statement PubMed 10085065. Source: ProtInc

   Cellular_componentblood microparticle

Inferred from direct assay PubMed 22516433. Source: UniProt

extracellular region

Traceable author statement. Source: Reactome

extracellular space

Inferred from direct assay PubMed 23580065. Source: UniProt

extracellular vesicular exosome

Inferred from direct assay PubMed 21362503. Source: UniProtKB

plasma membrane

Traceable author statement. Source: Reactome

   Molecular_functionC5L2 anaphylatoxin chemotactic receptor binding

Inferred from direct assay Ref.22. Source: UniProtKB

endopeptidase inhibitor activity

Inferred from electronic annotation. Source: InterPro

receptor binding

Traceable author statement PubMed 9164946. Source: ProtInc

Complete GO annotation...

Binary interactions

Sequence annotation (Features)

Feature keyPosition(s)LengthDescriptionGraphical viewFeature identifier

Molecule processing

Signal peptide1 – 2222 Ref.5
Chain23 – 16631641Complement C3
PRO_0000005907
Chain23 – 667645Complement C3 beta chain
PRO_0000005908
Chain672 – 1663992Complement C3 alpha chain
PRO_0000005909
Chain672 – 74877C3a anaphylatoxin
PRO_0000005910
Chain672 – 74776Acylation stimulating protein
PRO_0000419935
Chain749 – 1663915Complement C3b alpha' chain
PRO_0000005911
Chain749 – 954206Complement C3c alpha' chain fragment 1
PRO_0000005912
Chain955 – 1303349Complement C3dg fragment
PRO_0000005913
Chain955 – 100147Complement C3g fragment
PRO_0000005914
Chain1002 – 1303302Complement C3d fragment
PRO_0000005915
Peptide1304 – 132017Complement C3f fragment
PRO_0000005916
Chain1321 – 1663343Complement C3c alpha' chain fragment 2
PRO_0000273948

Regions

Domain693 – 72836Anaphylatoxin-like
Domain1518 – 1661144NTR
Region1424 – 145633Properdin-binding

Sites

Site747 – 7482Cleavage; by carboxypeptidases
Site748 – 7492Cleavage; by C3 convertase
Site954 – 9552Cleavage; by factor I Potential
Site1303 – 13042Cleavage; by factor I
Site1320 – 13212Cleavage; by factor I

Amino acid modifications

Glycosylation851N-linked (GlcNAc...) Ref.1 Ref.19 Ref.23 Ref.26 Ref.28 Ref.40 Ref.41
Glycosylation9391N-linked (GlcNAc...) Ref.20 Ref.23 Ref.40
Glycosylation16171N-linked (GlcNAc...) Ref.23
Disulfide bond559 ↔ 816Interchain (between beta and alpha chains) Ref.13 Ref.41
Disulfide bond627 ↔ 662 Ref.13 Ref.41
Disulfide bond693 ↔ 720 Ref.13 Ref.41
Disulfide bond694 ↔ 727 Ref.13 Ref.41
Disulfide bond707 ↔ 728 Ref.13 Ref.41
Disulfide bond873 ↔ 1513 Ref.13 Ref.41
Disulfide bond1101 ↔ 1158 Ref.13 Ref.41
Disulfide bond1358 ↔ 1489 Ref.13 Ref.41
Disulfide bond1389 ↔ 1458 Ref.13 Ref.41
Disulfide bond1506 ↔ 1511 Ref.13 Ref.41
Disulfide bond1518 ↔ 1590 Ref.13 Ref.41
Disulfide bond1537 ↔ 1661 Ref.13 Ref.41
Disulfide bond1637 ↔ 1646 Ref.13 Ref.41
Cross-link1010 ↔ 1013Isoglutamyl cysteine thioester (Cys-Gln)

Natural variations

Natural variant1021R → G in allele C3F; associated with ARMD9. Ref.2 Ref.47 Ref.50
Corresponds to variant rs2230199 [ dbSNP | Ensembl ].
VAR_001983
Natural variant3141P → L. Ref.1 Ref.2 Ref.47
Corresponds to variant rs1047286 [ dbSNP | Ensembl ].
VAR_001984
Natural variant4691E → D.
Corresponds to variant rs11569422 [ dbSNP | Ensembl ].
VAR_020262
Natural variant5491D → N in C3D; impairs secretion; variant confirmed at protein level. Ref.48 Ref.53
VAR_001985
Natural variant5921R → Q in AHUS5; leads to impaired binding to the regulator CD46/MCP and resistance to cleavage by factor I. Ref.51
VAR_063213
Natural variant5921R → W in AHUS5; leads to impaired binding to the regulator CD46/MCP and resistance to cleavage by factor I. Ref.51
VAR_063214
Natural variant6031F → V in AHUS5. Ref.52
VAR_063654
Natural variant7351R → W in AHUS5. Ref.51
Corresponds to variant rs117793540 [ dbSNP | Ensembl ].
VAR_063215
Natural variant8631R → K. Ref.2
Corresponds to variant rs11569472 [ dbSNP | Ensembl ].
VAR_019206
Natural variant10421R → L in AHUS5. Ref.52
VAR_063655
Natural variant10941A → V in AHUS5; leads to impaired binding to the regulator CD46/MCP and resistance to cleavage by factor I. Ref.51
VAR_063216
Natural variant11151D → N in AHUS5; leads to impaired binding to the regulator CD46/MCP and resistance to cleavage by factor I. Ref.51
VAR_063217
Natural variant11581C → W in AHUS5. Ref.51
VAR_063218
Natural variant11611Q → K in AHUS5; leads to impaired binding to the regulator CD46/MCP and resistance to cleavage by factor I. Ref.51
VAR_063219
Natural variant12161D → N in C3S. Ref.45
VAR_022761
Natural variant12241G → D. Ref.2
Corresponds to variant rs11569534 [ dbSNP | Ensembl ].
VAR_019207
Natural variant13201R → Q in C3D; allotype C3'F02'; may inhibit IC3B synthesis. Ref.49
VAR_001986
Natural variant13671I → T. Ref.2
Corresponds to variant rs11569541 [ dbSNP | Ensembl ].
VAR_019208
Natural variant14641H → D in AHUS5. Ref.51
VAR_063220
Natural variant15211Q → R.
Corresponds to variant rs7256789 [ dbSNP | Ensembl ].
VAR_029792
Natural variant16011H → N.
Corresponds to variant rs1803225 [ dbSNP | Ensembl ].
VAR_029793
Natural variant16191S → R.
Corresponds to variant rs2230210 [ dbSNP | Ensembl ].
VAR_029326

Experimental info

Mutagenesis10291D → A: Minor effect on binding of C3d to CR2. Ref.12 Ref.30 Ref.31
Mutagenesis10301E → A: Impaired binding of C3d to CR2. Ref.12 Ref.30 Ref.31
Mutagenesis10321E → A: Impaired binding of C3d to CR2. Ref.12 Ref.30 Ref.31
Mutagenesis10351E → A: No effect on binding of C3d to CR2. Ref.12 Ref.30
Mutagenesis10421R → M: Impaired binding of C3d to CR2. Ref.12 Ref.30
Mutagenesis1108 – 11092IL → RR: Impaired binding of C3d to CR2; when associated with A-1163. Ref.12
Mutagenesis11101E → A: No effect on binding of C3d to CR2. Ref.12 Ref.31
Mutagenesis11151D → A: No effect on binding of C3d to CR2. Ref.12 Ref.31
Mutagenesis11211D → A: No effect on binding of C3d to CR2. Ref.12 Ref.31
Mutagenesis11401D → A: No effect on binding of C3d to CR2. Ref.12 Ref.30 Ref.31
Mutagenesis11531E → A: Impaired binding of C3d to CR2. Ref.12 Ref.30 Ref.31
Mutagenesis11561D → A: Impaired binding of C3d to CR2. Ref.12 Ref.30 Ref.31
Mutagenesis11591E → A: Impaired binding of C3d to CR2. Ref.12 Ref.30 Ref.31
Mutagenesis11601E → A: Minor effect on binding of C3d to CR2. Ref.12 Ref.30 Ref.31
Mutagenesis11631N → A: No effect on binding of C3d to CR2. Impaired binding of C3d to CR2; when associated with 1108-R-R-1109. Ref.12 Ref.30 Ref.31 Ref.36
Mutagenesis11631N → R: Impaired binding of C3d to CR2. Ref.12 Ref.30 Ref.31 Ref.36
Mutagenesis12841K → A: Impaired binding of C3d to CR2. Ref.12 Ref.30
Sequence conflict6811D → N AA sequence Ref.6
Sequence conflict7001E → Q AA sequence Ref.6
Sequence conflict10261H → S AA sequence Ref.8

Secondary structure

........................................................................................................................................................................................................................................................................................................................... 1663
Helix Strand Turn

Details...

Sequences

Sequence LengthMass (Da)Tools
P01024 [UniParc].

Last modified December 12, 2006. Version 2.
Checksum: 30C2832A9E75FFC4

FASTA1,663187,148
        10         20         30         40         50         60 
MGPTSGPSLL LLLLTHLPLA LGSPMYSIIT PNILRLESEE TMVLEAHDAQ GDVPVTVTVH 

        70         80         90        100        110        120 
DFPGKKLVLS SEKTVLTPAT NHMGNVTFTI PANREFKSEK GRNKFVTVQA TFGTQVVEKV 

       130        140        150        160        170        180 
VLVSLQSGYL FIQTDKTIYT PGSTVLYRIF TVNHKLLPVG RTVMVNIENP EGIPVKQDSL 

       190        200        210        220        230        240 
SSQNQLGVLP LSWDIPELVN MGQWKIRAYY ENSPQQVFST EFEVKEYVLP SFEVIVEPTE 

       250        260        270        280        290        300 
KFYYIYNEKG LEVTITARFL YGKKVEGTAF VIFGIQDGEQ RISLPESLKR IPIEDGSGEV 

       310        320        330        340        350        360 
VLSRKVLLDG VQNPRAEDLV GKSLYVSATV ILHSGSDMVQ AERSGIPIVT SPYQIHFTKT 

       370        380        390        400        410        420 
PKYFKPGMPF DLMVFVTNPD GSPAYRVPVA VQGEDTVQSL TQGDGVAKLS INTHPSQKPL 

       430        440        450        460        470        480 
SITVRTKKQE LSEAEQATRT MQALPYSTVG NSNNYLHLSV LRTELRPGET LNVNFLLRMD 

       490        500        510        520        530        540 
RAHEAKIRYY TYLIMNKGRL LKAGRQVREP GQDLVVLPLS ITTDFIPSFR LVAYYTLIGA 

       550        560        570        580        590        600 
SGQREVVADS VWVDVKDSCV GSLVVKSGQS EDRQPVPGQQ MTLKIEGDHG ARVVLVAVDK 

       610        620        630        640        650        660 
GVFVLNKKNK LTQSKIWDVV EKADIGCTPG SGKDYAGVFS DAGLTFTSSS GQQTAQRAEL 

       670        680        690        700        710        720 
QCPQPAARRR RSVQLTEKRM DKVGKYPKEL RKCCEDGMRE NPMRFSCQRR TRFISLGEAC 

       730        740        750        760        770        780 
KKVFLDCCNY ITELRRQHAR ASHLGLARSN LDEDIIAEEN IVSRSEFPES WLWNVEDLKE 

       790        800        810        820        830        840 
PPKNGISTKL MNIFLKDSIT TWEILAVSMS DKKGICVADP FEVTVMQDFF IDLRLPYSVV 

       850        860        870        880        890        900 
RNEQVEIRAV LYNYRQNQEL KVRVELLHNP AFCSLATTKR RHQQTVTIPP KSSLSVPYVI 

       910        920        930        940        950        960 
VPLKTGLQEV EVKAAVYHHF ISDGVRKSLK VVPEGIRMNK TVAVRTLDPE RLGREGVQKE 

       970        980        990       1000       1010       1020 
DIPPADLSDQ VPDTESETRI LLQGTPVAQM TEDAVDAERL KHLIVTPSGC GEQNMIGMTP 

      1030       1040       1050       1060       1070       1080 
TVIAVHYLDE TEQWEKFGLE KRQGALELIK KGYTQQLAFR QPSSAFAAFV KRAPSTWLTA 

      1090       1100       1110       1120       1130       1140 
YVVKVFSLAV NLIAIDSQVL CGAVKWLILE KQKPDGVFQE DAPVIHQEMI GGLRNNNEKD 

      1150       1160       1170       1180       1190       1200 
MALTAFVLIS LQEAKDICEE QVNSLPGSIT KAGDFLEANY MNLQRSYTVA IAGYALAQMG 

      1210       1220       1230       1240       1250       1260 
RLKGPLLNKF LTTAKDKNRW EDPGKQLYNV EATSYALLAL LQLKDFDFVP PVVRWLNEQR 

      1270       1280       1290       1300       1310       1320 
YYGGGYGSTQ ATFMVFQALA QYQKDAPDHQ ELNLDVSLQL PSRSSKITHR IHWESASLLR 

      1330       1340       1350       1360       1370       1380 
SEETKENEGF TVTAEGKGQG TLSVVTMYHA KAKDQLTCNK FDLKVTIKPA PETEKRPQDA 

      1390       1400       1410       1420       1430       1440 
KNTMILEICT RYRGDQDATM SILDISMMTG FAPDTDDLKQ LANGVDRYIS KYELDKAFSD 

      1450       1460       1470       1480       1490       1500 
RNTLIIYLDK VSHSEDDCLA FKVHQYFNVE LIQPGAVKVY AYYNLEESCT RFYHPEKEDG 

      1510       1520       1530       1540       1550       1560 
KLNKLCRDEL CRCAEENCFI QKSDDKVTLE ERLDKACEPG VDYVYKTRLV KVQLSNDFDE 

      1570       1580       1590       1600       1610       1620 
YIMAIEQTIK SGSDEVQVGQ QRTFISPIKC REALKLEEKK HYLMWGLSSD FWGEKPNLSY 

      1630       1640       1650       1660 
IIGKDTWVEH WPEEDECQDE ENQKQCQDLG AFTESMVVFG CPN 

« Hide

References

« Hide 'large scale' references
[1]"Human complement component C3: cDNA coding sequence and derived primary structure."
de Bruijn M.H.L., Fey G.H.
Proc. Natl. Acad. Sci. U.S.A. 82:708-712(1985) [PubMed] [Europe PMC] [Abstract]
Cited for: NUCLEOTIDE SEQUENCE [MRNA], VARIANT LEU-314.
[2]SeattleSNPs variation discovery resource
Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANTS GLY-102; LEU-314; LYS-863; ASP-1224 AND THR-1367.
[3]Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., Turner R. expand/collapse author list , Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W., Venter J.C.
Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
[4]"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."
The MGC Project Team
Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
[5]"The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis."
Baldo A., Sniderman A.D., St-Luce S., Avramoglu R.K., Maslowska M., Hoang B., Monge J.C., Bell A., Mulay S., Cianflone K.
J. Clin. Invest. 92:1543-1547(1993) [PubMed] [Europe PMC] [Abstract]
Cited for: PROTEIN SEQUENCE OF N-TERMINUS, IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION.
[6]"Human anaphylatoxin (C3a) from the third component of complement. Primary structure."
Hugli T.E.
J. Biol. Chem. 250:8293-8301(1975) [PubMed] [Europe PMC] [Abstract]
Cited for: PROTEIN SEQUENCE OF 672-748.
[7]"Identification of angiotensinogen and complement C3dg as novel proteins binding the proform of eosinophil major basic protein in human pregnancy serum and plasma."
Oxvig C., Haaning J., Kristensen L., Wagner J.M., Rubin I., Stigbrand T., Gleich G.J., Sottrup-Jensen L.
J. Biol. Chem. 270:13645-13651(1995) [PubMed] [Europe PMC] [Abstract]
Cited for: PROTEIN SEQUENCE OF 955-966, SUBUNIT.
Tissue: Serum.
[8]"Third component of human complement: localization of the internal thiolester bond."
Thomas M.L., Janatova J., Gray W.R., Tack B.F.
Proc. Natl. Acad. Sci. U.S.A. 79:1054-1058(1982) [PubMed] [Europe PMC] [Abstract]
Cited for: PROTEIN SEQUENCE OF 988-1036.
[9]"A 34-amino acid peptide of the third component of complement mediates properdin binding."
Daoudaki M.E., Becherer J.D., Lambris J.D.
J. Immunol. 140:1577-1580(1988) [PubMed] [Europe PMC] [Abstract]
Cited for: PROTEIN SEQUENCE OF 1409-1563.
[10]"Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2."
Eisenberg R.J., Ponce de Leon M., Friedman H.M., Fries L.F., Frank M.M., Hastings J.C., Cohen G.H.
Microb. Pathog. 3:423-435(1987) [PubMed] [Europe PMC] [Abstract]
Cited for: INTERACTION WITH HERPES SIMPLEX VIRUS HHV-1 AND HHV-2 GYCOPROTEIN C.
[11]"Purification and characterization of acylation stimulating protein."
Cianflone K.M., Sniderman A.D., Walsh M.J., Vu H.T., Gagnon J., Rodriguez M.A.
J. Biol. Chem. 264:426-430(1989) [PubMed] [Europe PMC] [Abstract]
Cited for: FUNCTION.
[12]"Structural requirements for thioester bond formation in human complement component C3. Reassessment of the role of thioester bond integrity on the conformation of C3."
Isaac L., Isenman D.E.
J. Biol. Chem. 267:10062-10069(1992) [PubMed] [Europe PMC] [Abstract]
Cited for: MUTAGENESIS OF THE THIOESTER BOND REGION.
[13]"Disulfide bridges in human complement component C3b."
Dolmer K., Sottrup-Jensen L.
FEBS Lett. 315:85-90(1993) [PubMed] [Europe PMC] [Abstract]
Cited for: DISULFIDE BONDS.
[14]"Acylation-stimulating protein (ASP) regulates glucose transport in the rat L6 muscle cell line."
Tao Y., Cianflone K., Sniderman A.D., Colby-Germinario S.P., Germinario R.J.
Biochim. Biophys. Acta 1344:221-229(1997) [PubMed] [Europe PMC] [Abstract]
Cited for: FUNCTION.
[15]"Coordinated release of acylation stimulating protein (ASP) and triacylglycerol clearance by human adipose tissue in vivo in the postprandial period."
Saleh J., Summers L.K., Cianflone K., Fielding B.A., Sniderman A.D., Frayn K.N.
J. Lipid Res. 39:884-891(1998) [PubMed] [Europe PMC] [Abstract]
Cited for: IDENTIFICATION BY MASS SPECTROMETRY, TISSUE SPECIFICITY, FUNCTION.
[16]"Acylation-stimulating protein (ASP): structure-function determinants of cell surface binding and triacylglycerol synthetic activity."
Murray I., Kohl J., Cianflone K.
Biochem. J. 342:41-48(1999) [PubMed] [Europe PMC] [Abstract]
Cited for: FUNCTION.
[17]"The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des Arg(74)."
Cain S.A., Monk P.N.
J. Biol. Chem. 277:7165-7169(2002) [PubMed] [Europe PMC] [Abstract]
Cited for: INTERACTION WITH C5AR2.
[18]"The chemoattractant receptor-like protein C5L2 binds the C3a des-Arg77/acylation-stimulating protein."
Kalant D., Cain S.A., Maslowska M., Sniderman A.D., Cianflone K., Monk P.N.
J. Biol. Chem. 278:11123-11129(2003) [PubMed] [Europe PMC] [Abstract]
Cited for: INTERACTION WITH C5AR2.
[19]"Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry."
Zhang H., Li X.-J., Martin D.B., Aebersold R.
Nat. Biotechnol. 21:660-666(2003) [PubMed] [Europe PMC] [Abstract]
Cited for: GLYCOSYLATION AT ASN-85.
[20]"Screening for N-glycosylated proteins by liquid chromatography mass spectrometry."
Bunkenborg J., Pilch B.J., Podtelejnikov A.V., Wisniewski J.R.
Proteomics 4:454-465(2004) [PubMed] [Europe PMC] [Abstract]
Cited for: GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-939.
Tissue: Plasma.
[21]"Acylation-stimulating protein: effect of acute exercise and endurance training."
Schrauwen P., Hesselink M.K., Jain M., Cianflone K.
Int. J. Obes. Relat. Metab. Disord. 29:632-638(2005) [PubMed] [Europe PMC] [Abstract]
Cited for: EFFECTS OF EXERCISE.
[22]"C5L2 is a functional receptor for acylation-stimulating protein."
Kalant D., MacLaren R., Cui W., Samanta R., Monk P.N., Laporte S.A., Cianflone K.
J. Biol. Chem. 280:23936-23944(2005) [PubMed] [Europe PMC] [Abstract]
Cited for: FUNCTION, TISSUE SPECIFICITY.
[23]"Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry."
Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J., Smith R.D.
J. Proteome Res. 4:2070-2080(2005) [PubMed] [Europe PMC] [Abstract]
Cited for: GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-85; ASN-939 AND ASN-1617.
Tissue: Plasma.
[24]"Relationships among acylation stimulating protein, adiponectin and complement C3 in lean vs obese type 2 diabetes."
Yang Y., Lu H.L., Zhang J., Yu H.Y., Wang H.W., Zhang M.X., Cianflone K.
Int. J. Obes. Relat. Metab. Disord. 30:439-446(2006) [PubMed] [Europe PMC] [Abstract]
Cited for: ASSOCIATION WITH TYPE 2 DIABETES.
[25]"Targeting the signaling pathway of acylation stimulating protein."
Maslowska M., Legakis H., Assadi F., Cianflone K.
J. Lipid Res. 47:643-652(2006) [PubMed] [Europe PMC] [Abstract]
Cited for: IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION.
[26]"Elucidation of N-glycosylation sites on human platelet proteins: a glycoproteomic approach."
Lewandrowski U., Moebius J., Walter U., Sickmann A.
Mol. Cell. Proteomics 5:226-233(2006) [PubMed] [Europe PMC] [Abstract]
Cited for: GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-85.
Tissue: Platelet.
[27]"Acylation stimulating protein but not complement C3 associates with metabolic syndrome components in Chinese children and adolescents."
Wamba P.C., Mi J., Zhao X.Y., Zhang M.X., Wen Y., Cheng H., Hou D.Q., Cianflone K.
Eur. J. Endocrinol. 159:781-790(2008) [PubMed] [Europe PMC] [Abstract]
Cited for: ASSOCIATION WITH OBESITY.
[28]"Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry."
Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.
J. Proteome Res. 8:651-661(2009) [PubMed] [Europe PMC] [Abstract]
Cited for: GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-85.
Tissue: Liver.
[29]"C5a- and ASP-mediated C5L2 activation, endocytosis and recycling are lost in S323I-C5L2 mutation."
Cui W., Simaan M., Laporte S., Lodge R., Cianflone K.
Mol. Immunol. 46:3086-3098(2009) [PubMed] [Europe PMC] [Abstract]
Cited for: FUNCTION.
[30]"Mutational analyses reveal that the staphylococcal immune evasion molecule Sbi and complement receptor 2 (CR2) share overlapping contact residues on C3d: implications for the controversy regarding the CR2/C3d cocrystal structure."
Isenman D.E., Leung E., Mackay J.D., Bagby S., van den Elsen J.M.
J. Immunol. 184:1946-1955(2010) [PubMed] [Europe PMC] [Abstract]
Cited for: MUTAGENESIS OF ASP-1029; GLU-1030; GLU-1032; GLU-1035; ARG-1042; ASP-1140; GLU-1153; ASP-1156; GLU-1159; GLU-1160; ASN-1163 AND LYS-1284, INTERACTION WITH CR2 AND S.AUREUS SBI.
[31]"Delineation of the complement receptor type 2-C3d complex by site-directed mutagenesis and molecular docking."
Shaw C.D., Storek M.J., Young K.A., Kovacs J.M., Thurman J.M., Holers V.M., Hannan J.P.
J. Mol. Biol. 404:697-710(2010) [PubMed] [Europe PMC] [Abstract]
Cited for: MUTAGENESIS OF ASP-1029; GLU-1030; GLU-1032; GLU-1110; ASP-1115; ASP-1121; ASP-1140; GLU-1153; ASP-1156; GLU-1159; GLU-1160 AND ASN-1163, INTERACTION WITH CR2.
[32]"Serum complement C3: a determinant of cardiometabolic risk, additive to the metabolic syndrome, in middle-aged population."
Onat A., Hergenc G., Can G., Kaya Z., Yuksel H.
Metabolism 59:628-634(2010) [PubMed] [Europe PMC] [Abstract]
Cited for: ASSOCIATION WITH CORONARY HEART DISEASE.
[33]"Initial characterization of the human central proteome."
Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.
BMC Syst. Biol. 5:17-17(2011) [PubMed] [Europe PMC] [Abstract]
Cited for: IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
[34]"Secondary structure of complement component C3a anaphylatoxin in solution as determined by NMR spectroscopy: differences between crystal and solution conformations."
Nettesheim D.G., Edalji R.P., Mollison K.W., Greer J., Zuiderweg E.R.P.
Proc. Natl. Acad. Sci. U.S.A. 85:5036-5040(1988) [PubMed] [Europe PMC] [Abstract]
Cited for: STRUCTURE BY NMR OF C3A.
[35]"X-ray crystal structure of C3d: a C3 fragment and ligand for complement receptor 2."
Nagar B., Jones R.G., Diefenbach R.J., Isenman D.E., Rini J.M.
Science 280:1277-1281(1998) [PubMed] [Europe PMC] [Abstract]
Cited for: X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF C3D.
[36]"Structure of complement receptor 2 in complex with its C3d ligand."
Szakonyi G., Guthridge J.M., Li D., Young K., Holers V.M., Chen X.S.
Science 292:1725-1728(2001) [PubMed] [Europe PMC] [Abstract]
Cited for: X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF C3D IN COMPLEX WITH CR2, MUTAGENESIS OF 1108-ILE-LEU-1109 AND ASN-1163.
[37]"Solution structure of the complex between CR2 SCR 1-2 and C3d of human complement: an X-ray scattering and sedimentation modelling study."
Gilbert H.E., Eaton J.T., Hannan J.P., Holers V.M., Perkins S.J.
J. Mol. Biol. 346:859-873(2005) [PubMed] [Europe PMC] [Abstract]
Cited for: X-RAY SCATTERING SOLUTION STRUCTURE OF C3D IN COMPLEX WITH CR2.
[38]"Structures of complement component C3 provide insights into the function and evolution of immunity."
Janssen B.J.C., Huizinga E.G., Raaijmakers H.C.A., Roos A., Daha M.R., Nilsson-Ekdahl K., Nilsson B., Gros P.
Nature 437:505-511(2005) [PubMed] [Europe PMC] [Abstract]
Cited for: X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF C3C, X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF C3.
[39]"Structure of C3b reveals conformational changes that underlie complement activity."
Janssen B.J.C., Christodoulidou A., McCarthy A., Lambris J.D., Gros P.
Nature 444:213-216(2006) [PubMed] [Europe PMC] [Abstract]
Cited for: X-RAY CRYSTALLOGRAPHY (4.0 ANGSTROMS) OF C3B.
[40]"Structure of C3b in complex with CRIg gives insights into regulation of complement activation."
Wiesmann C., Katschke K.J., Yin J., Helmy K.Y., Steffek M., Fairbrother W.J., McCallum S.A., Embuscado L., DeForge L., Hass P.E., van Lookeren Campagne M.
Nature 444:217-220(2006) [PubMed] [Europe PMC] [Abstract]
Cited for: X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF C3C IN COMPLEX WITH VSIG4, X-RAY CRYSTALLOGRAPHY (4.1 ANGSTROMS) OF C3B IN COMPLEX WITH VSIG4, GLYCOSYLATION AT ASN-85 AND ASN-939.
[41]"Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition."
Janssen B.J., Halff E.F., Lambris J.D., Gros P.
J. Biol. Chem. 282:29241-29247(2007) [PubMed] [Europe PMC] [Abstract]
Cited for: X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 23-936 AND 1321-1663 IN COMPLEX WITH INHIBITOR COMPSTATIN, DISULFIDE BONDS, GLYCOSYLATION AT ASN-85.
[42]"A structural basis for complement inhibition by Staphylococcus aureus."
Hammel M., Sfyroera G., Ricklin D., Magotti P., Lambris J.D., Geisbrecht B.V.
Nat. Immunol. 8:430-437(2007) [PubMed] [Europe PMC] [Abstract]
Cited for: X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 996-1287 IN COMPLEX WITH S.AUREUS FIB.
[43]"A structural basis for Staphylococcal complement subversion: X-ray structure of the complement-binding domain of Staphylococcus aureus protein Sbi in complex with ligand C3d."
Clark E.A., Crennell S., Upadhyay A., Zozulya A.V., Mackay J.D., Svergun D.I., Bagby S., van den Elsen J.M.
Mol. Immunol. 48:452-462(2011) [PubMed] [Europe PMC] [Abstract]
Cited for: X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 996-1303 IN COMPLEX WITH S.AUREUS SBI, SUBUNIT.
[44]"A crystal structure of the complex between human complement receptor 2 and its ligand C3d."
van den Elsen J.M., Isenman D.E.
Science 332:608-611(2011) [PubMed] [Europe PMC] [Abstract]
Cited for: X-RAY CRYSTALLOGRAPHY (3.16 ANGSTROMS) OF 996-1303 IN COMPLEX WITH CR2, INTERACTION WITH CR2.
[45]"The difference between human C3F and C3S results from a single amino acid change from an asparagine to an aspartate residue at position 1216 on the alpha-chain of the complement component, C3."
Poznansky M.C., Clissold P.M., Lachmann P.J.
J. Immunol. 143:1254-1258(1989) [PubMed] [Europe PMC] [Abstract]
Cited for: VARIANT C3S ASN-1216.
[46]Erratum
Poznansky M.C., Clissold P.M., Lachmann P.J.
J. Immunol. 143:3860-3862(1989) [PubMed] [Europe PMC] [Abstract]
Cited for: RETRACTION.
[47]"Molecular basis of polymorphisms of human complement component C3."
Botto M., Yong Fong K., So A.K., Koch C., Walport M.J.
J. Exp. Med. 172:1011-1017(1990) [PubMed] [Europe PMC] [Abstract]
Cited for: VARIANTS GLY-102 AND LEU-314.
[48]"Inherited human complement C3 deficiency. An amino acid substitution in the beta-chain (Asp549 to Asn) impairs C3 secretion."
Singer L., Whitehead W.T., Akama H., Katz Y., Fishelson Z., Wetsel R.A.
J. Biol. Chem. 269:28494-28499(1994) [PubMed] [Europe PMC] [Abstract]
Cited for: VARIANT C3D ASN-549.
[49]"A novel C3 allotype C3'F02'has an amino acid substitution that may inhibit iC3b synthesis and cause C3-hypocomplementemia."
Watanabe Y., Matsui N., Yan K., Nishimukai H., Tokunaga K., Juji T., Kobayashi N., Kohsaka T.
Mol. Immunol. 30:62-62(1993)
Cited for: VARIANT C3D GLN-1320.
[50]"Complement C3 variant and the risk of age-related macular degeneration."
Yates J.R.W., Sepp T., Matharu B.K., Khan J.C., Thurlby D.A., Shahid H., Clayton D.G., Hayward C., Morgan J., Wright A.F., Armbrecht A.M., Dhillon B., Deary I.J., Redmond E., Bird A.C., Moore A.T.
N. Engl. J. Med. 357:553-561(2007) [PubMed] [Europe PMC] [Abstract]
Cited for: ASSOCIATION OF VARIANT GLY-102 WITH ARMD9.
[51]"Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome."
Fremeaux-Bacchi V., Miller E.C., Liszewski M.K., Strain L., Blouin J., Brown A.L., Moghal N., Kaplan B.S., Weiss R.A., Lhotta K., Kapur G., Mattoo T., Nivet H., Wong W., Gie S., Hurault de Ligny B., Fischbach M., Gupta R. expand/collapse author list , Hauhart R., Meunier V., Loirat C., Dragon-Durey M.A., Fridman W.H., Janssen B.J., Goodship T.H., Atkinson J.P.
Blood 112:4948-4952(2008) [PubMed] [Europe PMC] [Abstract]
Cited for: VARIANTS AHUS5 GLN-592; TRP-592; TRP-735; VAL-1094; ASN-1115; TRP-1158; LYS-1161 AND ASP-1464, CHARACTERIZATION OF VARIANTS AHUS5 GLN-592; TRP-592; VAL-1094; ASN-1115 AND LYS-1161.
[52]"Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome."
Maga T.K., Nishimura C.J., Weaver A.E., Frees K.L., Smith R.J.H.
Hum. Mutat. 31:E1445-E1460(2010) [PubMed] [Europe PMC] [Abstract]
Cited for: VARIANTS AHUS5 VAL-603 AND LEU-1042.
[53]"Quantitative detection of single amino acid polymorphisms by targeted proteomics."
Su Z.D., Sun L., Yu D.X., Li R.X., Li H.X., Yu Z.J., Sheng Q.H., Lin X., Zeng R., Wu J.R.
J. Mol. Cell Biol. 3:309-315(2011) [PubMed] [Europe PMC] [Abstract]
Cited for: VARIANT ASN-549, IDENTIFICATION BY MASS SPECTROMETRY.
+Additional computationally mapped references.

Web resources

C3base

C3 mutation db

GeneReviews
Wikipedia

Complement C3 entry

SeattleSNPs

Cross-references

Sequence databases

EMBL
GenBank
DDBJ
K02765 mRNA. Translation: AAA85332.1.
AY513239 Genomic DNA. Translation: AAR89906.1.
CH471139 Genomic DNA. Translation: EAW69071.1.
BC150179 mRNA. Translation: AAI50180.1.
BC150200 mRNA. Translation: AAI50201.1.
PIRC3HU. A94065.
RefSeqNP_000055.2. NM_000064.2.
UniGeneHs.529053.

3D structure databases

PDBe
RCSB PDB
PDBj
EntryMethodResolution (Å)ChainPositionsPDBsum
1C3DX-ray1.80A996-1287[»]
1GHQX-ray2.04A996-1300[»]
1W2SX-ray-A996-1299[»]
2A73X-ray3.30A23-665[»]
B673-1663[»]
2A74X-ray2.40A/D23-665[»]
B/E749-936[»]
C/F1321-1663[»]
2GOXX-ray2.20A/C996-1287[»]
2HR0X-ray2.26A23-667[»]
B749-1663[»]
2I07X-ray4.00A23-667[»]
B749-1663[»]
2ICEX-ray3.10A/D23-664[»]
B/E749-954[»]
C/F1321-1663[»]
2ICFX-ray4.10A23-664[»]
B749-1663[»]
2NOJX-ray2.70A/C/E/G996-1287[»]
2QKIX-ray2.40A/D23-665[»]
B/E749-936[»]
C/F1321-1663[»]
2WIIX-ray2.70A23-667[»]
B749-1663[»]
2WINX-ray3.90A/C/E/G23-667[»]
B/D/F/H749-1663[»]
2WY7X-ray1.70A996-1303[»]
2WY8X-ray1.70A996-1303[»]
2XQWX-ray2.31A/B996-1287[»]
2XWBX-ray3.49A/C23-664[»]
B/D752-1663[»]
2XWJX-ray4.00A/C/E/G23-667[»]
B/D/F/H749-1663[»]
3D5RX-ray2.10A/B996-1287[»]
3D5SX-ray2.30A/B996-1287[»]
3G6JX-ray3.10A/C23-666[»]
B/D749-1663[»]
3L3OX-ray3.40A/D23-667[»]
B/E749-954[»]
C/F1321-1663[»]
3L5NX-ray7.54A23-667[»]
B749-1663[»]
3NMSX-ray4.10A23-667[»]
B749-954[»]
C1321-1663[»]
3OEDX-ray3.16A/B996-1303[»]
3OHXX-ray3.50A/D23-667[»]
B/E749-954[»]
C/F1321-1663[»]
3OXUX-ray2.10A/B/C996-1303[»]
3RJ3X-ray2.35A/B/C996-1303[»]
3T4AX-ray3.40A/D23-667[»]
B/E749-954[»]
C/F1321-1663[»]
4HW5X-ray2.25A/B672-748[»]
4HWJX-ray2.60A672-747[»]
4I6OX-ray2.14A672-748[»]
4M76X-ray2.80A994-1288[»]
ProteinModelPortalP01024.
SMRP01024. Positions 23-664, 673-1663.
ModBaseSearch...
MobiDBSearch...

Protein-protein interaction databases

BioGrid107179. 14 interactions.
DIPDIP-35180N.
IntActP01024. 9 interactions.
MINTMINT-5003988.
STRING9606.ENSP00000245907.

Chemistry

BindingDBP01024.
ChEMBLCHEMBL4917.

Protein family/group databases

MEROPSI39.950.

PTM databases

PhosphoSiteP01024.
UniCarbKBP01024.

Polymorphism databases

DMDM119370332.

2D gel databases

DOSAC-COBS-2DPAGEP01024.
SWISS-2DPAGEP01024.

Proteomic databases

PaxDbP01024.
PeptideAtlasP01024.
PRIDEP01024.

Protocols and materials databases

StructuralBiologyKnowledgebaseSearch...

Genome annotation databases

EnsemblENST00000245907; ENSP00000245907; ENSG00000125730.
GeneID718.
KEGGhsa:718.
UCSCuc002mfm.3. human.

Organism-specific databases

CTD718.
GeneCardsGC19M006677.
H-InvDBHIX0020036.
HGNCHGNC:1318. C3.
HPACAB004209.
HPA003563.
HPA020432.
MIM120700. gene.
611378. phenotype.
612925. phenotype.
613779. phenotype.
neXtProtNX_P01024.
Orphanet279. Age-related macular degeneration.
93575. Atypical hemolytic uremic syndrome with C3 anomaly.
280133. Complement component 3 deficiency.
PharmGKBPA25897.
GenAtlasSearch...

Phylogenomic databases

eggNOGNOG241555.
HOGENOMHOG000286028.
HOVERGENHBG005110.
InParanoidP01024.
KOK03990.
OMAPGMPFDL.
OrthoDBEOG77HDCX.
PhylomeDBP01024.
TreeFamTF313285.

Enzyme and pathway databases

ReactomeREACT_111102. Signal Transduction.
REACT_6900. Immune System.

Gene expression databases

ArrayExpressP01024.
BgeeP01024.
CleanExHS_C3.
GenevestigatorP01024.

Family and domain databases

Gene3D1.20.91.20. 1 hit.
1.50.10.20. 1 hit.
2.60.40.690. 1 hit.
InterProIPR009048. A-macroglobulin_rcpt-bd.
IPR011626. A2M_comp.
IPR002890. A2M_N.
IPR011625. A2M_N_2.
IPR000020. Anaphylatoxin/fibulin.
IPR018081. Anaphylatoxin_comp_syst.
IPR001840. Anaphylatoxn_comp_syst_dom.
IPR001599. Macroglobln_a2.
IPR019742. MacrogloblnA2_CS.
IPR019565. MacrogloblnA2_thiol-ester-bond.
IPR001134. Netrin_domain.
IPR018933. Netrin_module_non-TIMP.
IPR008930. Terpenoid_cyclase/PrenylTrfase.
IPR008993. TIMP-like_OB-fold.
[Graphical view]
PfamPF00207. A2M. 1 hit.
PF07678. A2M_comp. 1 hit.
PF01835. A2M_N. 1 hit.
PF07703. A2M_N_2. 1 hit.
PF07677. A2M_recep. 1 hit.
PF01821. ANATO. 1 hit.
PF01759. NTR. 1 hit.
PF10569. Thiol-ester_cl. 1 hit.
[Graphical view]
PRINTSPR00004. ANAPHYLATOXN.
SMARTSM00104. ANATO. 1 hit.
SM00643. C345C. 1 hit.
[Graphical view]
SUPFAMSSF47686. SSF47686. 1 hit.
SSF48239. SSF48239. 1 hit.
SSF49410. SSF49410. 1 hit.
SSF50242. SSF50242. 1 hit.
PROSITEPS00477. ALPHA_2_MACROGLOBULIN. 1 hit.
PS01177. ANAPHYLATOXIN_1. 1 hit.
PS01178. ANAPHYLATOXIN_2. 1 hit.
PS50189. NTR. 1 hit.
[Graphical view]
ProtoNetSearch...

Other

ChiTaRSC3. human.
EvolutionaryTraceP01024.
GeneWikiComplement_component_3.
GenomeRNAi718.
NextBio2922.
PMAP-CutDBP01024.
PROP01024.
SOURCESearch...

Entry information

Entry nameCO3_HUMAN
AccessionPrimary (citable) accession number: P01024
Secondary accession number(s): A7E236
Entry history
Integrated into UniProtKB/Swiss-Prot: July 21, 1986
Last sequence update: December 12, 2006
Last modified: April 16, 2014
This is version 182 of the entry and version 2 of the sequence. [Complete history]
Entry statusReviewed (UniProtKB/Swiss-Prot)
Annotation programChordata Protein Annotation Program
DisclaimerAny medical or genetic information present in this entry is provided for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care.

Relevant documents

SIMILARITY comments

Index of protein domains and families

PDB cross-references

Index of Protein Data Bank (PDB) cross-references

MIM cross-references

Online Mendelian Inheritance in Man (MIM) cross-references in UniProtKB/Swiss-Prot

Human polymorphisms and disease mutations

Index of human polymorphisms and disease mutations

Human entries with polymorphisms or disease mutations

List of human entries with polymorphisms or disease mutations

Human chromosome 19

Human chromosome 19: entries, gene names and cross-references to MIM